Catalent commits $230 million to Harmans gene therapy campus

In order to meet customer demand, Catalent, a contract development and manufacturing organization (CDMO), is taking on a $230 million expansion project to add three additional commercial-scale viral vector manufacturing suites, and support facilities and services at its gene therapy campus in Harmans, MD.

This latest investment also includes expanding the site’s storage capabilities for just-in-time inventory space, ultra-low temperature freezers and its water-for-injection infrastructure.

The Harmans location is in close proximity to Baltimore Washington International Airport, and features a fully operational, FDA- and European Medicines Agency (EMA)-approved facility comprised of 10 commercial-scale manufacturing suites. The announcement follows a previous $130 million invested by the CDMO back in 2020, which is expected to bear fruit via five new manufacturing suites that are expected to be operational mid-2022. When the most recent construction project is completed at the end of next year, the campus will house a total of 18 current good manufacturing practice (cGMP) viral vector manufacturing suites.

The expansion is expected to result in the creation of 700 new jobs in the technical, scientific and operational spaces over the next six years.